Oct 20, 2022
Matty Culbreth-Notaro is the Chief Operations Officer at ObvioHealth and developing a new model for virtual decentralized clinical trials. Accelerated by the pandemic, there is widespread global acceptance of DCT. This digital solution and mobile app are an efficient approach to identifying and recruiting trial participants and significantly increasing trial completion rates.
Matty elaborates, "When I joined ObvioHealth, I had been in the industry for almost 30 years, I didn't know that it would actually work as well as it has. And now, being with Obvio for five years, I've seen the huge impact it's made, the technology has made to our patients, to our industry in general. And it's just been a great way for us to marry the tech and the service and leverage all the technological innovations that we have to tackle those inefficiencies in our industry."
"Our technology has built-in intelligence that it's able to say, well, you qualify, or you don't qualify, at least from the pre-screening questionnaire. And then, we send them, if they do qualify, a link to the app to download onto their smartphone. From there, we onboard them. We'll do the consenting process right on the phone. We'll ask them all the screening questionnaires right there. And then they're assigned to a virtual site team that's going to help them along the way. They're using their own smartphones to complete all of the study-related visits or study-related procedures."
"Now, not every trial can be done 100% in a decentralized way. Some trials have to be done with still a brick-and-mortar site involved in the process. And for that, that's called a hybrid model. We support that as well, so the participant can go to the office for some visits, but they don't have to go to the office for all the visits like they used to. And in many cases, none of this has to be done at the office anymore. It can be done remotely."
#ClinicalTrials #ObvioHealth #DecentralizedTrials #VirtualTrials #DCT #PatientEngagement #PatientCentricity #HybridClinicalTrials #DecentralizedClinicalTrials #DCTs #PatientAdherence #PatientCompliance #ClinicalResearch #RareDiseases